ZimVie (ZIMV) Competitors $9.26 +0.26 (+2.89%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$9.27 +0.01 (+0.11%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZIMV vs. MDXG, INMD, BBNX, KMTS, IRMD, SIBN, CBLL, EMBC, AVNS, and RXSTShould you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include MiMedx Group (MDXG), InMode (INMD), Beta Bionics (BBNX), Kestra Medical Technologies (KMTS), iRadimed (IRMD), SiBone (SIBN), CeriBell (CBLL), Embecta (EMBC), AVANOS MEDICAL (AVNS), and RxSight (RXST). These companies are all part of the "medical equipment" industry. ZimVie vs. Its Competitors MiMedx Group InMode Beta Bionics Kestra Medical Technologies iRadimed SiBone CeriBell Embecta AVANOS MEDICAL RxSight ZimVie (NASDAQ:ZIMV) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment. Is ZIMV or MDXG more profitable? MiMedx Group has a net margin of 11.40% compared to ZimVie's net margin of -4.40%. MiMedx Group's return on equity of 22.70% beat ZimVie's return on equity.Company Net Margins Return on Equity Return on Assets ZimVie-4.40% 5.53% 2.84% MiMedx Group 11.40%22.70%16.77% Which has preferable earnings & valuation, ZIMV or MDXG? MiMedx Group has lower revenue, but higher earnings than ZimVie. ZimVie is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimVie$449.75M0.57-$25.83M-$0.71-13.04MiMedx Group$348.88M2.51$42.42M$0.2722.00 Do institutionals & insiders believe in ZIMV or MDXG? 95.6% of ZimVie shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 5.4% of ZimVie shares are owned by company insiders. Comparatively, 1.7% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, ZIMV or MDXG? ZimVie has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Does the media refer more to ZIMV or MDXG? In the previous week, MiMedx Group had 1 more articles in the media than ZimVie. MarketBeat recorded 5 mentions for MiMedx Group and 4 mentions for ZimVie. MiMedx Group's average media sentiment score of 0.68 beat ZimVie's score of 0.62 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZimVie 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ZIMV or MDXG? ZimVie presently has a consensus price target of $16.33, indicating a potential upside of 76.39%. MiMedx Group has a consensus price target of $12.50, indicating a potential upside of 110.44%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts plainly believe MiMedx Group is more favorable than ZimVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZimVie 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.67MiMedx Group 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMiMedx Group beats ZimVie on 12 of the 17 factors compared between the two stocks. Get ZimVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIMV vs. The Competition Export to ExcelMetricZimVieMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$257.87M$10.44B$5.46B$8.92BDividend YieldN/A2.10%5.35%4.14%P/E Ratio-13.0417.8226.1519.64Price / Sales0.5731.06410.74112.88Price / Cash4.9923.5625.7827.49Price / Book0.673.637.875.41Net Income-$25.83M$235.40M$3.16B$248.99M7 Day Performance5.35%1.77%3.10%3.99%1 Month Performance3.23%0.15%4.62%4.82%1 Year Performance-49.26%-11.58%31.74%17.00% ZimVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIMVZimVie2.459 of 5 stars$9.26+2.9%$16.33+76.4%-49.3%$257.87M$449.75M-13.041,770News CoverageAnalyst UpgradeMDXGMiMedx Group3.557 of 5 stars$5.94+2.2%$12.50+110.4%-14.3%$858.15M$352.38M22.00870News CoverageINMDInMode3.6762 of 5 stars$13.49+1.6%$18.54+37.4%-22.2%$839.42M$394.82M5.79480BBNXBeta BionicsN/A$15.80-11.7%$23.44+48.4%N/A$775.64M$69.83M0.00294KMTSKestra Medical TechnologiesN/A$16.00+6.5%$27.50+71.9%N/A$771.77MN/A0.00300High Trading VolumeIRMDiRadimed4.7004 of 5 stars$59.49+2.1%$72.00+21.0%+38.5%$740.53M$73.24M38.38110Positive NewsSIBNSiBone4.1053 of 5 stars$16.52+0.8%$22.50+36.2%+42.5%$698.45M$167.18M-25.81350CBLLCeriBell2.7416 of 5 stars$18.49+3.2%$32.50+75.8%N/A$647.32M$65.44M0.00N/AAnalyst ForecastEMBCEmbecta4.4202 of 5 stars$9.82+0.5%$19.33+96.9%-22.9%$570.98M$1.12B10.912,100News CoverageNegative NewsAVNSAVANOS MEDICAL2.834 of 5 stars$12.09-0.4%N/A-38.7%$561.40M$687.80M-1.442,227RXSTRxSight2.9718 of 5 stars$13.54-0.5%$37.90+179.9%-78.9%$553.07M$139.93M-20.21220Positive News Related Companies and Tools Related Companies MiMedx Group Competitors InMode Competitors Beta Bionics Competitors Kestra Medical Technologies Competitors iRadimed Competitors SiBone Competitors CeriBell Competitors Embecta Competitors AVANOS MEDICAL Competitors RxSight Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIMV) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZimVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZimVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
